|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
<b>Methods:</b> PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors.
|
31106144 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> To evaluate the ability of texture analysis of breast dynamic contrast enhancement-magnetic resonance (DCE-MR) images in differentiating human epidermal growth factor receptor 2 (HER2) 2+ status of breast tumors.
|
31032222 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors.
|
11907566 |
2002 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Breast tumor development and progression are thought to occur through a complex, multistep process, including oncogene activation (eg HER2/neu) and mutation or loss of tumor suppressor genes (eg p53).
|
11250739 |
2001 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast tumors from women with Val/Val genotype were more likely to exhibit HER2 overexpression, but the results were not statistically significant (P = 0.17).
|
12846420 |
2003 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Breast tumors that express p95HER2 are resistant to trastuzumab and may require alternative or additional anti-HER2-targeting strategies.
|
17440164 |
2007 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Breast tumors that express p95HER2 are resistant to trastuzumab and may require alternative or additional anti-HER2-targeting strategies.
|
17440164 |
2007 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
|
18725974 |
2008 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Breast tumours with associated calcifications display an increased rate of HER2 overexpression as well as decreased survival, increased risk of recurrence, high tumour grade and increased likelihood of spread to the lymph nodes.
|
29684522 |
2018 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Breast tumor grade (<i>p</i> = 0.0001) and human epidermal growth factor receptor 2 status (<i>p</i> = 0.0262) were also statistically significant.
|
30941234 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
HER-2 status did not correlate with pathologic or clinical response (assessed by physical examination or imaging), although a nonsignificant trend was noted toward better response in patients with breast tumors that overexpressed HER-2.
|
12655533 |
2003 |
|
Mammary Neoplasms
|
0.500 |
Therapeutic
|
group |
CTD_human |
HER-2 status did not correlate with pathologic or clinical response (assessed by physical examination or imaging), although a nonsignificant trend was noted toward better response in patients with breast tumors that overexpressed HER-2.
|
12655533 |
2003 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
HER-2/neu gene in primary and local metastatic axillary lymph nodes in human breast tumors.
|
1634821 |
1992 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
HER2 overexpression is one of the most recognizable molecular alterations in breast tumors known to be associated with a poor prognosis.
|
16505105 |
2006 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
ERBB2 is frequently amplified in breast tumours as part of a wide region of amplification on chromosome 17q21.
|
17117180 |
2006 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
HER2, frequently associated with low p27 expression in breast tumors, when activated has been found to upmodulate p53 in tumor cells.
|
17604627 |
2007 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
ERBB2, AP-2alpha, and YY1 protein levels were analyzed by immunohistochemistry in a panel of 55 primary breast tumors.
|
18218085 |
2008 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-free and overall patient survival.
|
18316611 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-free and overall patient survival.
|
18316611 |
2008 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
ErbB-2 overexpression in breast tumors is associated with poor survival.
|
18469855 |
2008 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumors in relation to reproductive factors and exposure to exogenous hormones.
|
1920494 |
1991 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
HER2 overexpression is a hallmark of a particularly aggressive subset of breast tumors, and its activation is strictly dependent on the trans-interaction with other members of HER family; in particular, the activation of the PI3K/Akt survival pathway, so critically important in tumorigenesis, is predominantly driven through phosphorylation of the kinase-inactive member HER3.
|
19276373 |
2009 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
HER-2/neu protooncogene amplification and protein expression were analyzed with slot blot and Western blot techniques, respectively, in more than 300 invasive primary breast tumors of all stages.
|
1973070 |
1990 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
HER-2/neu predicts the sensitivity of breast tumors to trastuzumab and lapatinib.
|
21273092 |
2011 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
ERBB2 overexpression triggers transient high mechanoactivity of breast tumor cells.
|
22407943 |
2012 |